We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




New Generation of Antibiotics Disrupts Quorum Sensing

By LabMedica International staff writers
Posted on 24 Mar 2009
Drug developers are working on a new generation of antibiotics that do not kill bacteria but instead disrupt the communication system known as "quorum sensing,” which induces the microorganisms to manufacture disease-causing toxins.

Several types of bacteria, including such human pathogens as Vibrio cholerae and Escherichia coli O157:H7, can grow within a host without harming it, until they reach a certain concentration. More...
They become aggressive when their numbers become sufficient to overcome the host's immune system and form a biofilm, leading to disease. The language of quorum sensing is based on the bacterial population producing and detecting signaling molecules known as autoinducers.

Investigators from the Albert Einstein College of Medicine (New York, NY, USA) focused on the bacterial enzyme 5'-methylthioadenosine/S-adenosylhomocysteine nucleosidase (MTAN), which is involved in S-adenosylmethionine–related quorum sensing pathways that induce bacterial pathogenesis factors. To block MTAN activity they created a series of transition state analogs, MT-DADMe-Immucillin-A, EtT-DADMe-Immucillin-A, and BuT-DADMe-Immucillin-A, which are slow-onset, tight-binding inhibitors of V. cholerae MTAN (VcMTAN).

Results published in the March 8, 2009, online edition of the journal Nature Chemical Biology revealed that in V. cholerae cells, the compounds were potent MTAN inhibitors. Structural analysis of VcMTAN with BuT-DADMe-Immucillin-A revealed interactions contributing to the high affinity. The compounds disrupted autoinducer production in a dose-dependent manner without affecting growth. MT- and BuT-DADMe-Immucillin-A also inhibited autoinducer-2 production in enterohemorrhagic E. coli O157:H7.

By targeting quorum sensing rather than bacterial growth, the new drugs avoided stimulating the bacteria into becoming resistant. The investigators tested the compounds on 26 successive generations of both bacterial species, and found that the 26th generations were as sensitive to the antibiotics as the first. "In our lab, we call these agents everlasting antibiotics,” said senior author Dr. Vern Schramm, professor of biochemistry at Albert Einstein College of Medicine.

Related Links:

Albert Einstein College of Medicine



Gold Member
Fibrinolysis Assay
HemosIL Fibrinolysis Assay Panel
POC Helicobacter Pylori Test Kit
Hepy Urease Test
Automated MALDI-TOF MS System
EXS 3000
Gold Member
Immunochromatographic Assay
CRYPTO Cassette
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Hematology

view channel
Image: Residual leukemia cells may predict long-term survival in acute myeloid leukemia (Photo courtesy of Shutterstock)

MRD Tests Could Predict Survival in Leukemia Patients

Acute myeloid leukemia is an aggressive blood cancer that disrupts normal blood cell production and often relapses even after intensive treatment. Clinicians currently lack early, reliable markers to predict... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.